Keeping Track: Busy August Ends With Approval For Doravirine, CRLs For Dasotraline And Waylivra

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

The US FDA's Center for Drug Evaluation and Research (CDER) topped off its torrid August with an approval for Merck & Co. Inc.'s non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine, bringing the US FDA's novel drug approval count for the year to 34.

Slowing the growth of the total, however, was the issuance of complete response letters (CRLs) for Sunovion Pharmaceuticals Inc.'s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet